fludarabine phosphate has been researched along with Graft-Versus-Host Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afkhami, M; Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Cao, T; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Snyder, D; Stein, AS; Yang, D; Yang, L | 1 |
| Artz, A; De Lima, M; Giralt, S; Kunavakkam, R; Oran, B; Rondon, G; van Besien, K | 1 |
| Brunstein, CG; Cao, Q; Green, KG; Jacobson, PA; Long-Boyle, JR; McGlave, PB; Miller, JS; Rogosheske, J; Wagner, JE; Weisdorf, DJ | 1 |
| Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL | 1 |
| Esumi, T; Ichioka, N; Iida, H; Ikehara, S; Inaba, M; Kushida, T | 1 |
| Abali, H; Aksoy, S; Dinçer, M; Erman, M; Kilickap, S | 1 |
| Burnett, A; Dasgupta, RK; Davies, J; Jackson, G; Johnson, P; Morgan, GJ; Poynton, C; Richardson, C; Rule, S; Smith, GM; Stars, AC; Tollerfield, SM; Wareham, E; Wilson, K | 1 |
| Amir, G; Or, R; Polliack, A; Tejman, S; Weiss, L | 1 |
4 trial(s) available for fludarabine phosphate and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Vidarabine Phosphate; Young Adult | 2009 |
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Topics: Adult; Aged; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Neutrophil Infiltration; Prodrugs; Renal Insufficiency; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Vidarabine Phosphate; Young Adult | 2011 |
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Busulfan; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Recurrence; Survival Rate; Vidarabine Phosphate | 2012 |
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Melphalan; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate | 2006 |
4 other study(ies) available for fludarabine phosphate and Graft-Versus-Host Disease
| Article | Year |
|---|---|
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate | 2019 |
Successful allogeneic leg transplantation in rats in conjunction with intra-bone marrow injection of donor bone marrow cells.
Topics: Animals; Bone Marrow Transplantation; Female; Graft Survival; Graft vs Host Disease; Hindlimb; Immunosuppressive Agents; Rats; Rats, Inbred BN; Rats, Inbred F344; Transplantation Conditioning; Transplantation, Homologous; Vidarabine Phosphate; Whole-Body Irradiation | 2003 |
Fludarabine phosphate may be useful in the treatment of graft-versus-host disease.
Topics: Animals; Antimetabolites; Antineoplastic Agents; CD4 Lymphocyte Count; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukocyte Reduction Procedures; Leukopenia; Mice; Stem Cell Transplantation; T-Lymphocyte Subsets; Vidarabine Phosphate | 2005 |
The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models.
Topics: Animals; Bone Marrow Transplantation; Disease Models, Animal; Graft Survival; Graft vs Host Disease; Histocompatibility; Immunosuppressive Agents; Major Histocompatibility Complex; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Minor Histocompatibility Loci; Survival Rate; Transplantation Chimera; Vidarabine Phosphate; Weight Loss | 2000 |